A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Conditions
- Acute Lymphoblastic Leukemia
Interventions
- DRUG: inotuzumab ozogamicin
- DRUG: FLAG (fludarabine, cytarabine and G-CSF)
- DRUG: HIDAC (high dose cytarabine)
- DRUG: cytarabine and mitoxantrone
Sponsor
Pfizer
Collaborators